Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators.; UK ProtecT Study Collaborators.; PRACTICAL Consortium., Easton DF, Eeles RA, Kote-Jarai Z.

Br J Cancer. 2016 Apr 12;114(8):945-52.

2.

Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, Mcdonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokołorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Viñuela A, Brown AA; PRACTICAL Consortium.; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative.; Australian Prostate Cancer BioResource.; UK Genetic Prostate Cancer Study Collaborators.; UK ProtecT Study Collaborators., Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z.

Hum Mol Genet. 2015 Oct 1;24(19):5589-602. doi: 10.1093/hmg/ddv203. Epub 2015 May 29.

3.

Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study.

Wagenlehner FM, van Oostrum E, Tenke P, Tandogdu Z, Çek M, Grabe M, Wullt B, Pickard R, Naber KG, Pilatz A, Weidner W, Bjerklund-Johansen TE; GPIU investigators..

Eur Urol. 2013 Mar;63(3):521-7. doi: 10.1016/j.eururo.2012.06.003. Epub 2012 Jun 12.

PMID:
22704727
4.

Radical exenteration surgery is curative in locally advance mucinous prostatic adenocarcinoma involving bladder and rectum.

Koo VS, Lynn NN, Saxby MF.

J Surg Case Rep. 2010 Jun 1;2010(4):6. doi: 10.1093/jscr/2010.4.6.

5.

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.

Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology.; UK ProtecT Study Collaborators.; PRACTICAL Consortium., Easton DF.

Nat Genet. 2009 Oct;41(10):1116-21. doi: 10.1038/ng.450. Epub 2009 Sep 20.

6.

Multiple loci on 8q24 associated with prostate cancer susceptibility.

Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, English DR, Dearnaley DP, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Sawyer E, Lophatananon A; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology.; UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators., Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper C, Donovan JL, Hamdy FC, Neal DE, Eeles RA, Easton DF.

Nat Genet. 2009 Oct;41(10):1058-60. doi: 10.1038/ng.452. Epub 2009 Sep 20.

PMID:
19767752
7.

Associations between timing of exposure to ultraviolet radiation, T-stage and survival in prostate cancer.

Rukin N, Blagojevic M, Luscombe CJ, Liu S, Saxby MF, Ramachandran S, Fryer AA, Jones PW, Strange RC.

Cancer Detect Prev. 2007;31(6):443-9.

PMID:
18061372
8.

Prostate cancer susceptibility is mediated by interactions between exposure to ultraviolet radiation and polymorphisms in the 5' haplotype block of the vitamin D receptor gene.

Rukin NJ, Luscombe C, Moon S, Bodiwala D, Liu S, Saxby MF, Fryer AA, Alldersea J, Hoban PR, Strange RC.

Cancer Lett. 2007 Mar 18;247(2):328-35. Epub 2006 Jul 3.

PMID:
16815628
9.

Associations between G/A1229, A/G3944, T/C30875, C/T48200 and C/T65013 genotypes and haplotypes in the vitamin D receptor gene, ultraviolet radiation and susceptibility to prostate cancer.

Moon S, Holley S, Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC.

Ann Hum Genet. 2006 Mar;70(Pt 2):226-36.

10.

Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer.

Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC.

Environ Mol Mutagen. 2004;43(2):121-7.

PMID:
14991752
11.

Associations between prostate cancer susceptibility and parameters of exposure to ultraviolet radiation.

Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC.

Cancer Lett. 2003 Oct 28;200(2):141-8.

PMID:
14568167
12.

Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type.

Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Ramachandran S, Fryer AA, Strange RC.

Carcinogenesis. 2003 Apr;24(4):711-7.

PMID:
12727800
13.

Glutathione S-transferase GSTP1 genotypes are associated with response to androgen ablation therapy in advanced prostate cancer.

Luscombe CJ, French ME, Liu S, Saxby MF, Farrell WE, Jones PW, Fryer AA, Strange RC.

Cancer Detect Prev. 2002;26(5):376-80.

PMID:
12518868
14.

Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes.

Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC.

Br J Cancer. 2001 Nov 16;85(10):1504-9.

15.

Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes.

Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC.

Carcinogenesis. 2001 Sep;22(9):1343-7.

PMID:
11532853
16.

Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer.

Luscombe CJ, Fryer AA, French ME, Liu S, Saxby MF, Jones PW, Strange RC.

Lancet. 2001 Aug 25;358(9282):641-2.

PMID:
11530156
18.

A case-control study of percutaneous nephrolithotomy versus extracorporeal shock wave lithotripsy.

Saxby MF, Sorahan T, Slaney P, Coppinger SW.

Br J Urol. 1997 Mar;79(3):317-23.

PMID:
9117207
19.

Biliary peritonitis following percutaneous nephrolithotomy.

Saxby MF.

Br J Urol. 1996 Mar;77(3):465-6. No abstract available.

PMID:
8814863

Supplemental Content

Loading ...
Support Center